These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39477497)

  • 1. Comparison of Posttherapy 4- and 24-Hour [
    Swiha M; Pathmanandavel S; Papa N; Sabahi Z; Li S; Zheng A; Khan S; Ayers M; Sharma S; Crumbaker M; Nguyen A; Chan L; Ayati N; Emmett L
    J Nucl Med; 2024 Dec; 65(12):1939-1944. PubMed ID: 39477497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of rechallenge with [
    Santo G; Di Santo G; Sviridenko A; Bayerschmidt S; Wirth L; Scherbauer F; Lehmann P; von Guggenberg E; Decristoforo C; Heidegger-Pircher I; Bektic J; Virgolini I
    Eur J Nucl Med Mol Imaging; 2024 Dec; 52(1):354-365. PubMed ID: 39225826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving
    Demirci RA; Gulati R; Hawley JE; Yezefski T; Haffner MC; Cheng HH; Montgomery RB; Schweizer MT; Yu EY; Nelson PS; Chen DL; Iravani A
    J Nucl Med; 2024 Dec; 65(12):1945-1951. PubMed ID: 39510589
    [No Abstract]   [Full Text] [Related]  

  • 4. Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [
    Muniz M; Sartor O; Orme JJ; Koch RM; Rosenow HR; Mahmoud AM; Andrews JR; Kase AM; Riaz IB; Belge Bilgin G; Thorpe MP; Kendi AT; Johnson GB; Ravi P; Kwon ED; Childs DS
    J Nucl Med; 2024 Dec; 65(12):1932-1938. PubMed ID: 39477495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Significance of Baseline Clinical and [68Ga]Ga-PSMA PET Derived Parameters on Biochemical Response, Overall Survival, and PSA Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing [177Lu]Lu-PSMA Therapy.
    Jafari E; Manafi-Farid R; Ahmadzadehfar H; Salek F; Jokar N; Keshavarz A; Divband G; Dadgar H; Zohrabi F; Assadi M
    Nuklearmedizin; 2024 Dec; 63(6):347-358. PubMed ID: 39227023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSMA PET/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients.
    Kleiburg F; de Geus-Oei LF; Luelmo SAC; Spijkerman R; Goeman JJ; Toonen FAJ; Smit F; van der Hulle T; Heijmen L
    Eur J Radiol; 2024 Dec; 181():111774. PubMed ID: 39442347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theranostic Potential of the iPSMA-Bombesin Radioligand in Patients with Metastatic Prostate Cancer: A Pilot Study.
    González-Rueda S; García-Pérez O; Luna-Gutiérrez M; Ocampo-García B; Santos-Cuevas C; Ramírez-Nava G; Vargas-Ahumada J; Azorín-Vega E; Ferro-Flores G; Meléndez-Alafort L
    Pharmaceutics; 2024 Oct; 16(11):. PubMed ID: 39598482
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [
    Pabst KM; Mei R; Lückerath K; Hadaschik BA; Kesch C; Rawitzer J; Kessler L; Bodensieck LS; Hamacher R; Pomykala KL; Fanti S; Herrmann K; Fendler WP
    Eur J Nucl Med Mol Imaging; 2024 Dec; 52(1):342-353. PubMed ID: 39207485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single-center retrospective review of metastatic prostate cancer on PSMA position emission tomography/computed tomography: Beyond lymph nodes and bones.
    De Jesus GNC; Pereira V; Karak P; Shearier E
    Prostate; 2025 Jan; 85(1):13-20. PubMed ID: 39295117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study.
    Huang RR; Zuo C; Mona CE; Holzgreve A; Morrissey C; Nelson PS; Brady L; True L; Sisk A; Czernin J; Calais J; Ye H
    J Nucl Med; 2024 Dec; 65(12):1952-1958. PubMed ID: 39477498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline Nodal Status on
    Hofman MS; Kasivisvanathan V; Link E; Buteau J; Roberts MJ; Francis RJ; Tang C; Vela I; Thomas P; Rutherford N; Martin JM; Frydenberg M; Shakher R; Wong LM; Taubman K; Ting Lee S; Hsiao E; Roach P; Nottage M; Kirkwood I; Hayne D; Iravani A; Williams S; O'Brien J; Lawrentschuk N; Murphy DG
    Eur Urol Oncol; 2024 Nov; ():. PubMed ID: 39613566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Primary Staging of Selected Renal Tumours: Initial Experience in a Multicentre Cohort.
    Tariq A; Pearce A; Rhee H; Kyle S; Raveenthiran S; Pelecanos A; Gan CL; Goh JC; Wong D; McBean R; Marsh P; Goodman S; Dunglison N; Esler R; Navaratnam A; Yaxley JW; Thomas P; Pattison DA; Roberts MJ
    Eur Urol Focus; 2024 Sep; 10(5):770-778. PubMed ID: 38195354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial.
    Kim P; Sanchez AM; Penke TJR; Tuson HH; Kime JC; McKee RW; Slone WL; Conley NR; McMillan LJ; Prybol CJ; Garofolo PM
    Lancet Infect Dis; 2024 Dec; 24(12):1319-1332. PubMed ID: 39134085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radical prostatectomy versus deferred treatment for localised prostate cancer.
    Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicomponent psychosocial intervention to reduce substance use by adolescents involved in the criminal justice system: the RISKIT-CJS RCT.
    Coulton S; Nizalova O; Pellatt-Higgins T; Stevens A; Hendrie N; Marchand C; Vass R; Deluca P; Drummond C; Ferguson J; Waller G; Newbury-Birch D
    Public Health Res (Southampt); 2023 Mar; 11(3):1-77. PubMed ID: 37254608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lutetium-177-prostate-specific membrane antigen therapy for prostate cancer: current status and future prospects.
    Wong CH; Nicoletti R; Mazzone E; Eapen RS
    Curr Opin Urol; 2025 Jan; 35(1):46-52. PubMed ID: 39628406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the Potential Value of [ 68 Ga]Ga-FAPI-46 PET/CT for Molecular Assessment of Fibroblast Activation in Interstitial Lung Disease : A Single-Center Pilot Study.
    Bahtouee M; Jafari E; Khazaei M; Aram N; Amini A; Jokar N; Ahmadzadehfar H; Gholamrezanezhad A; Assadi M
    Clin Nucl Med; 2025 Jan; 50(1):e17-e25. PubMed ID: 39466620
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.